NCT06967961

Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 450 (estimated)
• Sponsor: Institut Claudius Regaud · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A prospective, proof-of-concept pilot study in patients with metastatic cancers (9 types of cancers are studied) treated at the IUCT-O or possibly in other institutions. Eligible patients will be selected and informed of this study during a medical consultation for their cancer by medical oncologists. Then, with the patient's consent and before the start of anti-cancer treatment (whatever the line), a blood sample will be taken to detect DP-circulating cells by 2 different methods of analysis. Each patient will participate in the study for one day. The methods of analysis will be: flow cytometry for all patients and either Parsotix® or CellSearch® depending on the type of cancer. 450 patients will be enrolled in total.

Conditions

• Urothelial Carcinoma
• Renal Cancer
• Prostate Adenocarcinoma
• Adenocarcinoma of Endometrium
• Cutaneous Melanoma
• Soft Tissue Sarcoma (STS)
• Nonseminomatous Germ Cell Tumor
• Seminomatous Germ Cell Tumor
• Upper Aerodigestive Tract Carcinoma
• Cervical Carcinoma

Interventions

Type	Name	Description
OTHER	For each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes:	A blood sample will be taken before initiation of the metastatic treatment line and will be analyzed by 2 distinct methods. The total blood volume withdrawn per patient is approximately 30mL.

Timeline

• Start date: 2025-07-23
• Primary completion: 2029-07-23
• Completion: 2029-07-23
• First posted: 2025-05-13
• Last updated: 2025-07-29

Locations

1 site across 1 country: France